DeepLife, 3billion Partner on Small-Molecule Drug Discovery

The collaboration pairs DeepLife's AI digital twins of human cells with 3billion's genomics and medicinal chemistry platform to target genetic modifiers of disease.

Updated on Nov. 9, 2026 in Biotech

Bold vector editorial illustration of teal and sage spherical cells linked by coral rods, with one mustard rod bent into a pocket, on a cream field.
DeepLife and 3billion announced a collaboration to discover small-molecule drugs targeting genetic modifiers that influence how severely a disease develops. AI Illustration. Upload story photo >

Paris-based techbio DeepLife and AI genomics company 3billion have announced a co-development collaboration to discover small-molecule therapeutics against genetic modifier targets. The partnership combines DeepLife's TwinCell platform with 3billion's AI-driven genomics and medicinal chemistry technology.

Why it matters

Genetic modifier targets influence whether and how severely a disease develops in people who carry the same disease-causing mutation, and may offer treatment routes where the underlying disease gene is difficult to drug directly. The collaboration aims to address that gap by linking causal disease modeling with compound design.

Company-reported figures put TwinCell's training base at more than 100 million harmonized single-cell omics data points and 3billion's reach at over 110,000 individuals tested and 2,000 healthcare professionals across more than 80 countries. These are self-reported platform metrics, and the collaboration's preclinical outcomes remain unreported.

The players

DeepLife

A Paris-based techbio company founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot that develops AI-powered digital twins of human cells.

3billion

An AI-powered genomics company founded in 2016 that specializes in rare disease diagnostics and drug discovery and serves healthcare professionals across more than 80 countries.

The details

DeepLife will use TwinCell to build causal models of disease from human single-cell and multi-omics data, while 3billion will confirm and characterize targets, including novel and allosteric binding pockets. 3billion will then apply its AI-driven medicinal chemistry platform to design candidate compounds, with the companies aiming to advance programs through preclinical and IND-enabling development.

Timeline

  1. 2016: 3billion is founded.

  2. 2019: DeepLife is founded by Jonathan Baptista and Jean-Baptiste Morlot.

  3. November 9, 2026: The collaboration is announced.

Big Picture

The partnership extends DeepLife's TwinCell digital twin platform, built on more than 100 million single-cell omics data points, from causal disease modeling into small-molecule drug design through 3billion's AI medicinal chemistry. It positions modifier-gene targeting as a route to therapies where the primary disease gene resists direct drugging.

For patients with rare genetic diseases, modifier-targeted drugs could eventually offer treatment options where direct gene correction is not feasible. Any resulting therapies remain in early development, with no approval or availability timeline stated.

The takeaway

AI platforms that model disease biology and design molecules are increasingly being combined across companies, and the value of modifier-gene approaches will depend on whether candidate compounds clear preclinical validation. Readers tracking biotech should watch for reported preclinical data before weighing the collaboration's potential.

Further reading

Explore more Biotech coverage for context on AI-driven drug discovery and digital disease modeling.

Source note: This article includes information reported by The Manila times.